Abstract

Since T2DM is suffered by most diabetic patients (around 90–95%), this review focuses on the potential drugs acting on multi-targets involved in treating this type of diabetes. T2D is distinguished by peripheral tissue insulin resistance (IR) and pancreatic beta-cell malfunction. It is also believed that obesity alters the body's metabolism. These modifications lead to the release of fat molecules into the circulation from fat tissue, which can impact insulin-responsive cells and decrease insulin sensitivity. Furthermore, Social and cultural aspects have significance for the approach to emergency treatment and curative consequences of obesity and type 2 diabetes. Regardless of the recent advances in the therapeutic management of diabetes, there are still many obstacles to overcome: enhancing our knowledge of how diabetes and obesity are interrelated. It is helpful to explain that an agent is simply one part of a multifaceted treatment plan when prescribed for a patient with T2DM and obesity. There should be thorough counselling on the predicted benefits, adverse effects, and cessation criteria. Obesity and T2DM significantly impact early mortality, condition of life, overweight-associated concurrent illnesses, and the global healthcare sector, whether they exist alone or together as "diabesity." Knowing the therapeutic and causal interactions between these two disorders is crucial.